Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy

Prostate. 2008 Sep 15;68(13):1380-6. doi: 10.1002/pros.20804.

Abstract

Background: Early detection of small volume prostate cancer (PCa) has led to the concept of focal therapy to treat in an organ-sparing manner. We evaluated trends in pathologic staging among patients with localized PCa undergoing radical prostatectomy (RP), defining the frequency of unilateral cancers during 1988-1995, 1996-2000 and 2001-2006.

Methods: Data were abstracted from the Duke Prostate Cancer Outcome database selecting 3,676 men with available pathology treated with RP. Based on surgical pathology, trends in as pathological T (pT) stage, pathological Gleason Score (pGS), and percent tumor involvement (PTI) were evaluated.

Results: pT2a increased from 2.8% of men undergoing RP in 1988-1995 to 13.0% during 2001-2006 (P < 0.0005). PTI analysis shifted towards low volume disease, e.g. PTI <or= 5% increased from 10% during 1988-1995, to 37% in 2001-2006 (P < 0.005). Of all pT2a disease throughout 1988-2006, an increase in proportion of pT2a tumors from 10% during 1988-1995 to 69.4% during 2001-2006 was identified. Over three eras, pT2a had minimal (65% had PTI <or= 5%) or small volume (14% had PTI 5.01-10.00) disease, and 59% were low grade (pGS <or= 6). Using a Cox Hazard model, pT2a versus pT2b disease, surgical margins, PTI, and PSA statistically contributed to PSA disease-free survival in the contemporary era 2001-2006.

Conclusions: The increasing prevalence of unilateral pT2a/T2b PCa characterizes a growing proportion of men recently electing RP. These tumors are associated with lower PTI, pGS <or= 7, and demonstrated better PSA-free survival in the 2001-2006 era. These low risk pathologic characteristics may allow for unilateral focal therapy in carefully selected patients.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood
  • Disease-Free Survival
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Mass Screening
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood*
  • Prostatectomy / trends*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery*
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen